Acute Kidney Injury in Cancer Patients
View More View Less
  • 1 Memorial Sloan Kettering Cancer Center, New York, NY
  • | 2 Weill Cornell Medical College, New York, NY
  • | 3 Memorial Sloan Kettering Cancer Center, Renal Service New York, NY
  • | 4 Weill Cornell Medical College, New York, NY
  • 1

    Siegel RL, Miller KD, Jemal A: Cancer statistics, 2020. CA Cancer J Clin 70: 730, 2020 PubMed

  • 2

    Postow MA, Sidlow R, Hellmann MD: Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378: 158168, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3

    Kinsey GR, Sharma R, Okusa MD: Regulatory T cells in AKI. J Am Soc Nephrol 24: 17201726, 2013 PubMed

  • 4

    Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, et al.: Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90: 638647, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5

    Seethapathy H, Zhao S, Chute DF, Zubiri L, Oppong Y, Strohbehn I, et al.: The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol 14: 16921700, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6

    Shirali AC, Perazella MA, Gettinger S: Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis 68: 287291, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7

    Izzedine H, Mathian A, Champiat S, Picard C, Mateus C, Routier E, et al.: Renal toxicities associated with pembrolizumab. Clin Kidney J 12: 8188, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8

    Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, et al.: Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: Single-center experience. J Immunother Cancer 7: 2, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9

    Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, et al.: Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: A multicenter study. J Am Soc Nephrol 31: 435446, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10

    Kitchlu A, Fingrut W, Avila-Casado C, Chan CT, Crump M, Hogg D, et al.: Nephrotic syndrome with cancer immunotherapies: A report of 2 cases. Am J Kidney Dis 70: 581585, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11

    Takahashi N, Tsuji K, Tamiya H, Shinohara T, Kuroda N, Takeuchi E: Goodpasture’s disease in a patient with advanced lung cancer treated with nivolumab: An autopsy case report. Lung Cancer 122: 2224, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12

    Daanen RA, Maas RJH, Koornstra RHT, Steenbergen EJ, van Herpen CML, Willemsen AECAB: Nivolumab-associated nephrotic syndrome in a patient with renal cell carcinoma: A case report. J Immunother 40: 345348, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13

    Gupta S, Short SAP, Sise ME, Prosek JM, Madhavan SM, Soler MJ, et al.; ICPi-AKI Consortium Investigators: Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer 9: e003467, 2021 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14

    Lin JS, Mamlouk O, Selamet U, Tchakarov A, Glass WF, Sheth RA, et al.: Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. OncoImmunology 10: 1877415, 2021 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15

    Murakami N, Mulvaney P, Danesh M, Abudayyeh A, Diab A, Abdel-Wahab N, et al.; Immune Checkpoint Inhibitors in Solid Organ Transplant Consortium: A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int 100: 196205, 2021 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16

    Monteith BE, Venner CP, Reece DE, Kew AK, Lalancette M, Garland JS, et al.: Drug-induced thrombotic microangiopathy with concurrent proteasome inhibitor use in the treatment of multiple myeloma: A case series and review of the literature. Clin Lymphoma Myeloma Leuk 20: e791e800, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17

    Yui JC, Van Keer J, Weiss BM, Waxman AJ, Palmer MB, D’Agati VD, et al.: Proteasome inhibitor associated thrombotic microangiopathy. Am J Hematol 91: E348E352, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18

    Ball S, Behera TR, Anwer F, Chakraborty R: Risk of kidney toxicity with carfilzomib in multiple myeloma: A meta-analysis of randomized controlled trials. Ann Hematol 99: 12651271, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19

    Chen Y, Ooi M, Lim SF, Lin A, Lee J, Nagarajan C, et al.: Thrombotic microangiopathy during carfilzomib use: Case series in Singapore. Blood Cancer J 6: e450, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20

    Zibetti Dal Molin G, Westin SN, Msaouel P, Gomes LM, Dickens A, Coleman RL: Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. Int J Gynecol Cancer 30: 8993, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21

    McCormick A, Swaisland H: In vitro assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparib. Xenobiotica 47: 903915, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22

    Bruin MAC, Korse CM, van Wijnen B, de Jong VMT, Linn SC, van Triest B, et al.: A real or apparent decrease in glomerular filtration rate in patients using olaparib? Eur J Clin Pharmacol 77: 179188, 2021 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23

    Ettl J: Management of adverse events due to cyclin-dependent kinase 4/6 inhibitors. Breast Care (Basel) 14: 8692, 2019 PubMed

  • 24

    Chappell JC, Turner PK, Pak YA, Bacon J, Chiang AY, Royalty J, et al.: Abemaciclib inhibits renal tubular secretion without changing glomerular filtration rate. Clin Pharmacol Ther 105: 11871195, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25

    Thill M, Schmidt M: Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol 10: 1758835918793326, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26

    Da Silva A, Chretien B, Alexandre J, Emile G: Abemaciclib-induced reversible grade 4 nephrotoxicity. Breast J 26: 23292330, 2020 PubMed

  • 27

    Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, et al.: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358: 11291136, 2008 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28

    Bollée G, Patey N, Cazajous G, Robert C, Goujon JM, Fakhouri F, et al.: Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 24: 682685, 2009 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29

    Overkleeft EN, Goldschmeding R, van Reekum F, Voest EE, Verheul HM: Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib. Ann Oncol 21: 184185, 2010 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30

    Izzedine H, Mangier M, Ory V, Zhang SY, Sendeyo K, Bouachi K, et al.: Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int 85: 457470, 2014 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31

    Winn SK, Ellis S, Savage P, Sampson S, Marsh JE: Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: A class effect? Nephrol Dial Transplant 24: 673675, 2009 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 32

    Delsante M, Monroy-Trujillo JM, Carter-Monroe N, Ball DW, Rosenberg AZ: Lenvatinib-related renal microangiopathy: A case series [published online ahead of print May 6, 2021]. Virchows Arch 10.1007/s00428-021-03114-5PubMed

    • Search Google Scholar
    • Export Citation
  • 33

    Pfister F, Amann K, Daniel C, Klewer M, Büttner A, Büttner-Herold M: Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy. Histopathology 73: 9901001, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 34

    Furuto Y, Hashimoto H, Namikawa A, Outi H, Takahashi H, Horiuti H, et al.: Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: A case report. BMC Nephrol 19: 273, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35

    Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al.: Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377: 25312544, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 36

    Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al.; JULIET Investigators: Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380: 4556, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 37

    Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al.: Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378: 449459, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 38

    Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, et al.: Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: An expert panel opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 25: 23052321, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 39

    Jhaveri KD, Rosner MH: Chimeric antigen receptor T cell therapy and the kidney: What the nephrologist needs to know. Clin J Am Soc Nephrol 13: 796798, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 40

    Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al.: ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25: 625638, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 41

    Frey N, Porter D: Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant 25: e123e127, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 42

    Gutgarts V, Jain T, Zheng J, Maloy MA, Ruiz JD, Pennisi M, et al.: Acute kidney injury after CAR-T cell therapy: Low incidence and rapid recovery. Biol Blood Marrow Transplant 26: 10711076, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 43

    Gupta S, Seethapathy H, Strohbehn IA, Frigault MJ, O’Donnell EK, Jacobson CA, et al.: Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma. Am J Kidney Dis 76: 6371, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 44

    Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al.: Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 15: 4762, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 45

    Durlacher-Betzer K, Hassan A, Levi R, Axelrod J, Silver J, Naveh-Many T: Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease. Kidney Int 94: 315325, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 46

    Dixon BN, Daley RJ, Buie LW, Hsu M, Park JH, Brentjens RJ, et al.: Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells. Clin Nephrol 93: 4246, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 47

    Bruining DM, van Roon EN, de Graaf H, Hoogendoorn M: Cyclophosphamide-induced symptomatic hyponatraemia. Neth J Med 69: 192195, 2011 PubMed

    • Search Google Scholar
    • Export Citation
  • 48

    Hingorani S: Renal complications of hematopoietic-cell transplantation. N Engl J Med 374: 22562267, 2016 PubMed

  • 49

    Kersting S, Dorp SV, Theobald M, Verdonck LF: Acute renal failure after nonmyeloablative stem cell transplantation in adults. Biol Blood Marrow Transplant 14: 125131, 2008 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 50

    Satwani P, Bavishi S, Jin Z, Jacobson JS, Baker C, Duffy D, et al.: Risk factors associated with kidney injury and the impact of kidney injury on overall survival in pediatric recipients following allogeneic stem cell transplant. Biol Blood Marrow Transplant 17: 14721480, 2011 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 51

    Gutgarts V, Sathick IJ, Zheng J, Politikos I, Devlin SM, Maloy MA, et al.: Incidence and risk factors for acute and chronic kidney injury after adult cord blood transplantation. Biol Blood Marrow Transplant 26: 758763, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 52

    Hingorani SR, Guthrie K, Batchelder A, Schoch G, Aboulhosn N, Manchion J, et al.: Acute renal failure after myeloablative hematopoietic cell transplant: Incidence and risk factors. Kidney Int 67: 272277, 2005 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 53

    Mae H, Ooi J, Takahashi S, Tomonari A, Tsukada N, Konuma T, et al.: Early renal injury after myeloablative cord blood transplantation in adults. Leuk Lymphoma 49: 538542, 2008 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 54

    Spitzer TR: Engraftment syndrome: Double-edged sword of hematopoietic cell transplants. Bone Marrow Transplant 50: 469475, 2015 PubMed

  • 55

    Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al.: Hepatic veno-occlusive disease following stem cell transplantation: Incidence, clinical course, and outcome. Biol Blood Marrow Transplant 16: 157168, 2010 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 56

    Richardson PG, Grupp SA, Pagliuca A, Krishnan A, Ho VT, Corbacioglu S: Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure. Int J Hematol Oncol 6: 7593, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 57

    Kojouri K, George JN: Thrombotic microangiopathy following allogeneic hematopoietic stem cell transplantation. Curr Opin Oncol 19: 148154, 2007 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 58

    Changsirikulchai S, Myerson D, Guthrie KA, McDonald GB, Alpers CE, Hingorani SR: Renal thrombotic microangiopathy after hematopoietic cell transplant: Role of GVHD in pathogenesis. Clin J Am Soc Nephrol 4: 345353, 2009 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 59

    Wanchoo R, Bayer RL, Bassil C, Jhaveri KD: Emerging concepts in hematopoietic stem cell transplantation-associated renal thrombotic microangiopathy and prospects for new treatments. Am J Kidney Dis 72: 857865, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 60

    Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, et al.: Blood and marrow transplant clinical trials network toxicity committee consensus summary: Thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11: 571575, 2005 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 61

    Dvorak CC, Higham C, Shimano KA: Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: A practical approach to diagnosis and management. Front Pediatr 7: 133, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 62

    Nakamae H, Yamane T, Hasegawa T, Nakamae M, Terada Y, Hagihara K, et al.: Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. Am J Hematol 81: 525531, 2006 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 63

    Uderzo C, Bonanomi S, Busca A, Renoldi M, Ferrari P, Iacobelli M, et al.: Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation 82: 638644, 2006 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 64

    Shayani S, Palmer J, Stiller T, Liu X, Thomas SH, Khuu T, et al.: Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 19: 298304, 2013 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 65

    Li A, Wu Q, Davis C, Kirtane KS, Pham PD, Sorror ML, et al.: Transplant-associated thrombotic microangiopathy is a multifactorial disease unresponsive to immunosuppressant withdrawal. Biol Blood Marrow Transplant 25: 570576, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 66

    Kraft S, Bollinger N, Bodenmann B, Heim D, Bucher C, Lengerke C, et al.: High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease. Bone Marrow Transplant 54: 540548, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 67

    Arai Y, Yamashita K, Mizugishi K, Watanabe T, Sakamoto S, Kitano T, et al.: Serum neutrophil extracellular trap levels predict thrombotic microangiopathy after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 19: 16831689, 2013 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 68

    Haines HL, Laskin BL, Goebel J, Davies SM, Yin HJ, Lawrence J, et al.: Blood, and not urine, BK viral load predicts renal outcome in children with hemorrhagic cystitis following hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 17: 15121519, 2011 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 69

    Sawinski D, Trofe-Clark J: BK virus nephropathy. Clin J Am Soc Nephrol 13: 18931896, 2018 PubMed

  • 70

    Park YH, Lim JH, Yi HG, Lee MH, Kim CS: BK virus-hemorrhagic cystitis following allogeneic stem cell transplantation: Clinical characteristics and utility of leflunomide treatment. Turk J Haematol 33: 223230, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 71

    Gaziev J, Paba P, Miano R, Germani S, Sodani P, Bove P, et al.: Late-onset hemorrhagic cystitis in children after hematopoietic stem cell transplantation for thalassemia and sickle cell anemia: A prospective evaluation of polyoma (BK) virus infection and treatment with cidofovir. Biol Blood Marrow Transplant 16: 662671, 2010 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 72

    Nesselhauf N, Strutt J, Bastani B: Evaluation of leflunomide for the treatment of BK viremia and biopsy proven BK nephropathy; a single center experience. J Nephropathol 5: 3437, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 73

    Philippe M, Ranchon F, Gilis L, Schwiertz V, Vantard N, Ader F, et al.: Cidofovir in the treatment of BK virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 22: 723730, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 74

    Renaghan AD, Jaimes EA, Malyszko J, Perazella MA, Sprangers B, Rosner MH: Acute kidney injury and CKD associated with hematopoietic stem cell transplantation. Clin J Am Soc Nephrol 15: 289297, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 75

    Krishnappa V, Gupta M, Manu G, Kwatra S, Owusu O-T, Raina R: Acute kidney injury in hematopoietic stem cell transplantation: A review. Int J Nephrol 2016: 5163789, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 76

    Miura K, Sekine T, Takamizawa M, Terashima H, Furuya A, Koh K, et al.: Early occurrence of nephrotic syndrome associated with cord blood stem cell transplantation. Clin Exp Nephrol 16: 180182, 2012 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 77

    Brukamp K, Doyle AM, Bloom RD, Bunin N, Tomaszewski JE, Cizman B: Nephrotic syndrome after hematopoietic cell transplantation: Do glomerular lesions represent renal graft-versus-host disease? Clin J Am Soc Nephrol 1: 685694, 2006 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 78

    Beyar-Katz O, Davila EK, Zuckerman T, Fineman R, Haddad N, Okasha D, et al.: Adult nephrotic syndrome after hematopoietic stem cell transplantation: Renal pathology is the best predictor of response to therapy. Biol Blood Marrow Transplant 22: 975981, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 79

    Kim JY, Lee MY, Kim B, Park CW, Chang YS, Chung S: Membranoproliferative glomerulonephritis following allogeneic hematopoietic stem cell transplantation. Clin Exp Nephrol 14: 630632, 2010 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 80

    Hu SL, Colvin GA, Rifai A, Suzuki H, Novak J, Esparza A, et al.: Glomerulonephritis after hematopoietic cell transplantation: IgA nephropathy with increased excretion of galactose-deficient IgA1. Nephrol Dial Transplant 25: 17081713, 2010 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 81

    Huang X, Qin W, Zhang M, Zheng C, Zeng C, Liu Z: Detection of anti-PLA2R autoantibodies and IgG subclasses in post-allogeneic hematopoietic stem cell transplantation membranous nephropathy. Am J Med Sci 346: 3237, 2013 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 82

    Sadeghi B, Al-Chaqmaqchi H, Al-Hashmi S, Brodin D, Hassan Z, Abedi-Valugerdi M, et al.: Early-phase GVHD gene expression profile in target versus non-target tissues: Kidney, a possible target? Bone Marrow Transplant 48: 284293, 2013 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 83

    Hingorani S, Guthrie KA, Schoch G, Weiss NS, McDonald GB: Chronic kidney disease in long-term survivors of hematopoietic cell transplant. Bone Marrow Transplant 39: 223229, 2007 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 84

    Ando M, Ohashi K, Akiyama H, Sakamaki H, Morito T, Tsuchiya K, et al.: Chronic kidney disease in long-term survivors of myeloablative allogeneic haematopoietic cell transplantation: Prevalence and risk factors. Nephrol Dial Transplant 25: 278282, 2010 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 85

    Hingorani S, Pao E, Stevenson P, Schoch G, Laskin BL, Gooley T, et al.: Changes in glomerular filtration rate and impact on long-term survival among adults after hematopoietic cell transplantation: A prospective cohort study. Clin J Am Soc Nephrol 13: 866873, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 86

    Glezerman IG, Devlin S, Maloy M, Bui M, Jaimes EA, Giralt SA, et al.: Long term renal survival in patients undergoing T-cell depleted versus conventional hematopoietic stem cell transplants. Bone Marrow Transplant 52: 733738, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 87

    Jacoby E, Chen A, Loeb DM, Gamper CJ, Zambidis E, Llosa NJ, et al.: Single-agent post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis after human leukocyte antigen-matched related bone marrow transplantation for pediatric and young adult patients with hematologic malignancies. Biol Blood Marrow Transplant 22: 112118, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 88

    Hingorani S, Gooley T, Pao E, Sandmaier B, McDonald G: Urinary cytokines after HCT: Evidence for renal inflammation in the pathogenesis of proteinuria and kidney disease. Bone Marrow Transplant 49: 403409, 2014 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 89

    Hingorani S, Finn LS, Pao E, Lawler R, Schoch G, McDonald GB, et al.: Urinary elafin and kidney injury in hematopoietic cell transplant recipients. Clin J Am Soc Nephrol 10: 1220, 2015 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 124 124 70
Full Text Views 112 112 86
PDF Downloads 162 162 121